Bicara Therapeutics BCAX Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — operating income (loss)?
- Bicara Therapeutics (BCAX) reported business segments — operating income (loss) of -$60.24M in Q1 2026.
- How has Bicara Therapeutics's business segments — operating income (loss) changed year-over-year?
- Bicara Therapeutics's business segments — operating income (loss) decreased by 44.2% year-over-year, from -$41.79M to -$60.24M.
- What is the long-term trend for Bicara Therapeutics's business segments — operating income (loss)?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — operating income (loss) has grown at a 97.5% compound annual growth rate (CAGR), from -$39.89M to -$155.6M.
- What does business segments — operating income (loss) mean?
- This metric represents the profit or loss generated by the company's primary business activities, calculated by subtracting total operating expenses from total operating revenues. It serves as a key indicator of the core operational efficiency and the sustainability of the company's research and development-focused business model before accounting for financing or tax impacts.